Kiniksa Pharmaceuticals Ltd (KNSA) — Cash Flow Reinvestment Rate
Kiniksa Pharmaceuticals Ltd (KNSA) has a Cash Flow Reinvestment Rate of 1.55x as of June 2026, reinvesting $73.58 Million (capex $663.00K plus investments $-72.92 Million) from operating cash flow of $47.46 Million. See Kiniksa Pharmaceuticals Ltd (KNSA) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Kiniksa Pharmaceuticals Ltd Cash Flow Reinvestment Rate (2022–2025)
Historical reinvestment intensity for Kiniksa Pharmaceuticals Ltd across 4 annual periods. For the full cash flow conversion analysis, see KNSA cash flow conversion.
Annual Cash Flow Reinvestment Rate for Kiniksa Pharmaceuticals Ltd (2022–2025)
Year-by-year capital reinvestment analysis for Kiniksa Pharmaceuticals Ltd. See Kiniksa Pharmaceuticals Ltd financial flexibility index to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 7.31x | $187.70 Million | $25.69 Million | $277.00K | ▲ +394.6% |
| 2024 | 1.48x | $37.95 Million | $25.69 Million | $277.00K | ▼ -65.8% |
| 2023 | 4.32x | $57.45 Million | $13.30 Million | $130.00K | ▲ +207.1% |
| 2022 | 1.41x | $8.17 Million | $5.81 Million | $105.00K | — |